Evidence map›Paper›PMID 40295032›Full record

ArticleIn vivo (Athens, Greece)

Chad R Schultz, Martin C H Gruhlke, Alan J Slusarenko, André S Bachmann

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chad R SchultzDepartment of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, U.S.A.
Martin C H GruhlkeSociety for Natural Product and Drug Research (GENAWIF), Aachen, Germany.
Alan J SlusarenkoSociety for Natural Product and Drug Research (GENAWIF), Aachen, Germany.
André S BachmannDepartment of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, U.S.A.; bachma26@msu.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimAllicin is a small-molecule natural product found in garlic (Allium sativum). We previously showed that allicin inhibits ornithine decarboxylase (ODC) MATERIALS AND

methodsIn this study, we used cell proliferation assays, immunoblotting techniques, and light microscopy to study NB tumor cell cultures and human primary neonatal skin fibroblast control cells as well as a

resultsAllicin strongly inhibits NB tumor cell proliferation in a dose-dependent manner while non-cancerous human primary neonatal skin fibroblast control cells were largely unaffected. Importantly, two intra-tumoral injections of allicin over a two-week trial period significantly reduced the NB tumor burden in mice compared to controls (N=4-9 mice/group). Excised tumor tissues revealed that allicin treatment increased the cyclin-dependent kinase inhibitor p27

conclusionOur findings warrant further preclinical development of allicin as a potential anticancer agent, especially for those types of cancers that are treatable by intra-tumoral injections, including neuroblastoma, glioblastoma, and medulloblastoma.

Indexed as

Antineoplastic AgentsNeuroblastomaSulfinic AcidsAnimalsApoptosisCell Line, TumorCell ProliferationChildCyclin-Dependent Kinase Inhibitor p27Disease Models, AnimalDisulfidesHumansMiceXenograft Model Antitumor AssaysallicinAntineoplastic AgentsCyclin-Dependent Kinase Inhibitor p27DisulfidesSulfinic AcidsAllicinchildhood cancerintra-tumoral injectionin vivo antitumor activitynatural productsneuroblastomapatient-derived xenograft (PDX)

Identifiers

PMID40295032
PMCPMC12041990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.